SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about press release

06 Jul 2022 Evaluate
Aurobindo Pharma has informed that it enclosed Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities, a wholly owned subsidiary of the Company, for Triamcinolone Acetonide Injectable Suspension.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1377.65 -8.00 (-0.58%)
20-Apr-2026 11:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.45
Dr. Reddys Lab 1235.50
Cipla 1236.00
Zydus Lifesciences 939.75
Lupin 2332.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×